Cargando…
Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience
Systemic chemotherapy or chemoradiotherapy is the initial primary option for patients with locally advanced pancreatic cancer (LAPC). This study analyzed the effect of FOLFIRINOX and assessed the factors influencing conversion to surgical resectability for LAPC. Sixty-four patients with LAPC who rec...
Autores principales: | Lee, Jongchan, Lee, Jong-chan, Gromski, Mark A., Kim, Hyoung Woo, Kim, Jinwon, Kim, Jaihwan, Hwang, Jin-Hyeok |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320053/ https://www.ncbi.nlm.nih.gov/pubmed/30558029 http://dx.doi.org/10.1097/MD.0000000000013592 |
Ejemplares similares
-
Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer
por: Jung, Jae Hyup, et al.
Publicado: (2022) -
Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients
por: Shin, Dong Woo, et al.
Publicado: (2021) -
Postoperative muscle mass restoration as a prognostic factor in patients with resected pancreatic cancer
por: Lee, Jongchan, et al.
Publicado: (2020) -
Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment
por: Jung, Jae Hyup, et al.
Publicado: (2020) -
Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX
por: Kim, Jinkook, et al.
Publicado: (2021)